Fennec Pharmaceuticals (FENC) Misses Q3 EPS by 11c

Fennec Pharmaceuticals (NASDAQ: FENC) reported Q3 EPS of ($0.21), $0.11 worse than the analyst estimate of ($0.10). Revenue for the quarter came in at $6.97 million versus the consensus estimate of $8.82 million.

For earnings history and earnings-related data on Fennec Pharmaceuticals (FENC) click here.

You May Also Be Interested In

• Trump on Iran: we're trying to work out a deal that's fair
• Wealthfront launches custodial account with tax-gain harvesting
• Backblaze (BLZE) call put ratio 12.9 calls to 1 put with a focus on July 12.50 calls as share price up 40%